Rizatriptan Benzoate Tablet
Product Images NDC 71335-2536

Product Visual Gallery

This gallery contains 5 technical images submitted to the FDA as part of the official labeling for Rizatriptan Benzoate (NDC 71335-2536). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Bryant Ranch Prepack, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Label (Lbl713352536)

Rizatriptan Benzoate Tablets, USP 5 mg oral tablets label showing 30 tablets per container. The label includes the NDC 71335-2536-1, manufacturer Aurobindo Pharma Limited, and repackager Bryant Ranch Prepack, Inc. Storage instructions and dispersal warnings are also present on the label.*

FDA Label Image

Figure 1: Estimated Probability Of Achieving An Initial Headache Response By 2 Hours In Pooled Studies 1, 2, 3, And 4†† (Rizatriptan Fig1)

A Kaplan-Meier plot showing the estimated probability of achieving an initial headache response by 2 hours post-dose in pooled studies. The graph compares placebo, Rizatriptan Benzoate 5 mg, and Rizatriptan Benzoate 10 mg, illustrating higher response rates over time for both doses compared to placebo.*

FDA Label Image

Figure 2: Estimated Probability Of Patients Taking A Second Dose Of Rizatriptan Benzoate Tablets Or Other Medication For Migraines Over The 24 Hours Following The Initial Dose Of Study Treatment In Pooled Studies 1, 2, 3, And 4††† (Rizatriptan Fig2)

A Kaplan-Meier plot showing the estimated probability over 24 hours post-dose of patients taking a second dose of Rizatriptan Benzoate tablets 5 mg and 10 mg or placebo for migraines in pooled clinical studies. The y-axis represents the estimated probability of remediation or rescue, while the x-axis represents hours post-dose. Three lines compare placebo, Rizatriptan Benzoate 5 mg, and 10 mg.*

FDA Label Image

Figure3 (Rizatriptan Fig3)

A line graph comparing the percentage response over time (in hours post Stage 2 dose) between Rizatriptan Benzoate orally disintegrating tablets and placebo. The x-axis represents hours post dose (0.5 to 2 hours), while the y-axis shows the percentage with 95% confidence intervals. Rizatriptan shows a higher percentage increase than placebo over time.*

FDA Label Image

Chemical Structure (Rizatriptan Str)

Chemical structure of Rizatriptan Benzoate showing molecular connectivity and arrangement of atoms including indole, triazole, and benzoate functional groups.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.